IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,825 shares of the medical research company’s stock after purchasing an additional 3,015 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IQVIA were worth $15,821,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its stake in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in IQVIA in the 2nd quarter worth approximately $27,000. Rise Advisors LLC acquired a new stake in shares of IQVIA in the first quarter valued at approximately $31,000. Riverview Trust Co acquired a new position in IQVIA during the first quarter worth $32,000. Finally, Covestor Ltd grew its holdings in shares of IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 1.1 %

NYSE IQV traded down $2.82 during mid-day trading on Friday, reaching $247.97. 257,344 shares of the company’s stock traded hands, compared to its average volume of 1,052,323. The company has a fifty day simple moving average of $229.89 and a 200-day simple moving average of $233.85. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a market cap of $45.18 billion, a price-to-earnings ratio of 33.77, a P/E/G ratio of 2.26 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.22 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.24 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Truist Financial upped their price objective on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Morgan Stanley boosted their price target on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Tuesday. Argus raised shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Evercore ISI increased their price objective on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $265.67.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.